Takeda Pharmaceuticals USA, a fully owned subsidiary of Takeda Pharmaceutical Company, has partnered with Foundation Medicine to work on companion diagnostics for late-stage lung cancer portfolio.
The partnership aims to develop Foundation Medicine’s tissue and blood-based FoundationOne CDx and FoundationOne Liquid CDx tests for use with Takeda’s marketed and investigational treatments for late-stage lung cancer.
The suitable companion diagnostics will be used to identify patients who may be eligible for mobocertinib, if approved.
Mobocertinib is an investigational drug being evaluated for the treatment of patients with a range of conditions, including epidermal growth factor receptor (EGFR) Exon 20 insertion+ metastatic non-small cell lung cancer (mNSCLC) and ALUNBRIG (brigatinib).
Takeda Oncology Therapeutic Area Unit head Christopher Arendt said: “Our collaboration with Foundation Medicine will address an urgent need for broad access to genomic tests, ultimately expanding treatment options and potentially improving outcomes for people with ALK+ and EGFR Exon 20 insertion+ mNSCLC.
“Robust, accurate and timely testing is crucial to enable oncologists to make informed treatment decisions so that advanced cancer patients receive the optimal therapy for their disease.”
Foundation Medicine maintains a portfolio of Food and Drug Administration (FDA)-approved genomic profiling tests. The company provides physicians with both blood- and tissue-based testing options for detecting genomic alterations, which helps to guide personalised treatment decisions.
The company developed FoundationOne CDx and FoundationOne assays to enable oncologists to detect patients who may be appropriate for FDA-approved targeted therapies.
Foundation Medicine CEO Cindy Perettie said: “We are proud to partner with Takeda on this important journey to allow more lung cancer patients to have access to genomic testing to inform personalised treatment decisions.
“Takeda shares our patient-centric approach to research and development and mission to advance personalised cancer care. This collaboration, leveraging our portfolio of FDA-approved genomic tests, will accelerate our shared vision and make precision medicine a reality for more patients.”
Last month, Foundation Medicine received the FDA approval for its pan-tumour liquid biopsy test FoundationOne Liquid CDx.